Current Preclinical and Clinical Evidence of Shock Wave Therapy for Spinal Cord Injury: A Systematic Review.
Sofie Nagele, Berit Zellmer, Michael Graber...
https://pubmed.ncbi.nlm.nih.gov/42041555/Actively Recruiting
Led by AUVA · Updated on 2024-02-01
246
Participants Needed
15
Research Sites
N/A
Total Duration
Researchers are investigating the effects of extracorporeal shock wave therapy ESWT on patients with acute traumatic spinal cord injury SCI. SCI causes primary mechanical damage to the spinal cord followed by secondary injury processes that worsen neurological function. The study aims to intervene early, within 48 hours of injury, to reduce neuronal damage by targeting the secondary injury phase. Previous animal studies have shown that ESWT may improve nerve regeneration and motor function after SCI. The trial compares two groups one receiving ESWT applied once at the spinal cord lesion and surrounding segments, plus the soles of both feet, and a control group receiving a sham procedure without shock waves. The treatment is given as soon as possible within 48 hours post-injury. The device used is the Orthogold 100 shockwave generator. The study is randomized, double-blind, and placebo-controlled to assess ESWTs impact. Participants will be evaluated over six months, with measurements including changes in motor scores, sensory function, spasticity, walking ability, urological function, hand grip tests, and independence in daily life. Safety is monitored through adverse event reporting during the first 21 days. The study tracks neurological function changes from baseline to six months to understand ESWTs potential to improve recovery after acute SCI.
CONDITIONS
NEUROwave - Extracorporeal Shock Wave Therapy (ESWT) in Acute Traumatic Complete (AIS A) and Incomplete (AIS B-D) Cross-sectional Lesions on Motor and Sensory Function Within Six Months After Injury
W
Wolfgang Schaden, Dr
I
Iris Leister, MSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AUVA
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single treatment within 48 hours post-injury
Participants receive extracorporeal shock wave therapy or a sham procedure applied once within 48 hours after injury.
1 treatment visit (in-person)
Duration - Up to 6 months
Participants are monitored for motor and sensory function, spasticity, walking ability, urological function, grip ability, and adverse events for up to 6 months after treatment.
Multiple follow-up visits over 6 months
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Sofie Nagele, Berit Zellmer, Michael Graber...
https://pubmed.ncbi.nlm.nih.gov/42041555/Iris Leister, Rainer Mittermayr, Georg Mattiassich...
https://pubmed.ncbi.nlm.nih.gov/35365190/AUVA
Lead Sponsor